SCHEMBL5168155

SCHEMBL5168155

[CH2]CCCOC(F)(F)C(F)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10344919 0.93
SCHEMBL10344890 0.91
SCHEMBL1498091 0.85
SCHEMBL21069189 0.85
SCHEMBL5168029 0.82
SCHEMBL3155618 0.79
SCHEMBL10993824 0.79
SCHEMBL11897945 0.78
SCHEMBL28701219 0.76
SCHEMBL2517597 0.76 ADRB2 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970146-B1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR ABBVIE DEUTSCHLAND (DE) 2017-11-01 EP disclosed
EP-2909201-B1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR ABBVIE DEUTSCHLAND (DE) 2017-02-22 EP disclosed
US-9388141-B2 Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor ABBVIE INC. (US) 2016-07-12 US disclosed
US-9388148-B2 Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor ABBVIE INC. (US) 2016-07-12 US disclosed
US-9376396-B2 Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor AbbVie Deutschland GmbH & Co. KG (DE) 2016-06-28 US disclosed
US-20140303176-A1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2014-10-09 US disclosed
US-20140275104-A1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2014-09-18 US disclosed
US-20140194437-A1 ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR AbbVie Deutschland GmbH & Co. KG (DE) 2014-07-10 US disclosed
EP-0949231-B1 FLUORINE-SUBSTITUTED BENZENE DERIVATIVES, LIQUID-CRYSTAL COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENT CHISSO CORP (JP) 2007-05-02 EP disclosed
US-6210603-B1 HIGH VOLTAGE HOLDING RATIO, ALTERED ONLY SLIGHTLY BY CHANGE OF TEMPERATURE, AND LOW THRESHOLD VOLTAGE CHISSO CORPORATION (JP) 2001-04-03 US disclosed
EP-0949231-A1 FLUORINE-SUBSTITUTED BENZENE DERIVATIVES, LIQUID-CRYSTAL COMPOSITION, AND LIQUID-CRYSTAL DISPLAY ELEMENT CHISSO CORPORATION (JP) 1999-10-13 EP disclosed
EP-0113127-B1 PROCESS FOR PREPARING DIORGANOPOLYSILOXANE CONTAINING FLUOROALKYL GROUPS Wacker-Chemie GmbH (DE) 1990-03-07 EP disclosed
US-4577040-A Method for preparing diorganopolysiloxanes containing fluoroalkyl groups WACKER-CHEMIE GMBH (DE) 1986-03-18 US disclosed
US-4549004-A ANTIFOAM LUBRICANT WACKER-CHEMIE GMBH (DE) 1985-10-22 US disclosed
US-4489201-A Fluoroalkyloxylakyl containing organopolysiloxanes WACKER-CHEMIE GMBH (DE) 1984-12-18 US disclosed
EP-0113127-A2 Process for preparing diorganopolysiloxane containing fluoroalkyl groups Wacker-Chemie GmbH (DE) 1984-07-11 EP disclosed